Journal Article10.1128/CMR.12.1.40
Current and Emerging Azole Antifungal Agents
1.1K
TL;DR: Present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections are described and a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles is provided.
read more
Abstract: Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
The combination of antifungal compound and modifier of proton homeostasis for destroying or growth inhibition and reproduction of fungi
Bagar Tanja,Bencina Mojca,Medved Natasa +2 more
- 07 Sep 2010
TL;DR: In this paper, the combination of an antifungal substance and a proton homeostasis modifier was used for enhancing the fungicidic or fungistatic action of the anti-fungal agent for treating or preventing fungal infections.
1
Synthesis, Molecular Docking and Biological Evaluation of 2-(2-hydrazinyl)thiazoles as Potential Antioxidant, Anti-inflammatory and Anticancer Agent.
Dattatraya G. Raut,Raghunath B. Bhosale,A. S. Lawand,Mahesh G. Hublikar,Vikas D. Kadu,S. B. Patil,Prafulla B. Choudhari +6 more
TL;DR: 2-(2-Hydrazinyl)thiazoles derivatives showed significant anticancer activity for human leukemia cell line K-562 compared to Adriamycin as a reference standard and provide an interesting template for design and development new antioxidant, anti-inflammatory and anti-cancer agents.
1
•Dissertation
Drug-drug interactions between antiretrovirals and fluconazole in HIV-infected patients
Desire Fouche
- 01 Mar 2012
TL;DR: No significant effects of fluconazole on the pharmacokinetics of any of the studied ARVs were observed and Varying efavirenz plasma concentrations in different ethnic populations may be due to differences in gene expression particularly CYP2B6.
Occidiofungin, an actin binding antifungal with in vivo efficacy in a vulvovaginal candidiasis infection
Akshaya Ravichandran,Mengxin Geng,Mengxin Geng,Mengxin Geng,Mengxin Geng,Mengxin Geng,Mengxin Geng,Kenneth G. Hull,Daniel Romo,Shi-En Lu,Albee A,Nutter C,Donna M. Gordon,Mahmoud A. Ghannoum,Lockless Sw,Laura N. Smith,Laura N. Smith,Laura N. Smith,Laura N. Smith,Laura N. Smith,Laura N. Smith +20 more
TL;DR: It is established that occidiofungin is an efficacious compound with a novel molecular target, putting it in a completely new class of antifungals, which could fill the existing gap in treatment options for fungal infections.
Systemische Mykosen
F. Müller1,M. Weig2 +1 more
- 01 Feb 2003
TL;DR: This study investigates systemic mycoses, a group of fungal infections affecting multiple body systems, with a focus on epidemiology, clinical manifestations, and treatment options, highlighting the need for improved diagnostic and therapeutic strategies.
1
References
•Book
Principles and Practice of Infectious Diseases
Gerald L. Mandell,R. Gordon Douglas,John E. Bennett +2 more
- 01 Mar 1989
TL;DR: This updated and expanded edition now offers 297 chapters that cover the basic principles of diagnosis and management, major clinical syndromes, all important pathogenic microbes and the diseases they cause, plus a number of specialised topics useful to the practitioner.
14.4K
National Committee for Clinical Laboratory Standards.
TL;DR: Many members of the Academy of Pediatrics seem to be generally unaware of the fact that the Academy has participated for ten years in a very interesting and valuable organization, the National Committee for Clinical Laboratory Standards (NCCLS).
14.1K
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
TL;DR: This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.
1.4K
The Merck Index
TL;DR: The Merck Index of Chemicals and Drugs is an encyclopedia for the Chemist, Pharmacist, Physician and Allied Professions and thumb-indexed, 8 dollars.
1.3K